Tag-Archive for ◊ medtronic ◊

• Tuesday, January 21st, 2014

Boston Scientific Corp. (BSX) won’t begin a study of its hypertension treatment until it can analyze a failed effort by Medtronic Inc. (MDT) and review its approach with U.S. regulators, Chief Executive Officer Michael Mahoney said. While Boston Scientific has Food and Drug Administration backing to start a pivotal trial of its Vessix technology, the company is waiting […]

• Wednesday, December 11th, 2013

American doctors have begun implanting a new deep-brain stimulation system by Medtronic Inc. that senses and records brain activity at the same time it delivers therapy to treat Parkinson’s symptoms, essential tremors and epilepsy, the company announced Thursday. The Activa PC+S deep-brain stimulation system may allow researchers to actually make the link to brain signals […]

• Friday, December 06th, 2013

Medtronic’s cardiac and vascular group president, Michael Coyle, questions CardioMEMS’ implantable heart monitor, citing Medtronic’s experience with its now-abandoned Chronicle monitor. The Champion implantable heart monitor made by CardioMEMS might not prove as cost-effective as a non-invasive approach, at least according to Medtronic (NYSE:MDT) cardiac and vascular group president Michael Coyle. Coyle, speaking at the 25th Annual […]

• Wednesday, December 04th, 2013

Medtronic Surgical Technologies has completed a $14 million, 17,000-square-foot surgical training facility at its headquarters in Jacksonville, Fla. The facility, which is known as the Dr. Glen Nelson Surgeon Education and Training Center, will provide training for surgeons in cranial, spinal and ear, nose and throat procedures. It is named for Glen Nelson, a practicing […]

• Wednesday, November 20th, 2013

(Reuters) – A new generation of Medtronic Inc’s EnRhythm pacemaker programmed to kick in only when heart rhythm disturbances are detected led to fewer deaths, hospitalizations and incidences of developing permanent heart problems than traditional versions of the device, according to data from a study. The enhanced pacing strategy had its most profound effect in […]

• Wednesday, November 20th, 2013

The FDA slaps its highest-risk Class I status on Medtronic’s recall after at least 1 patient is reportedly injured by a broken coronary surgery guidewire. MASSDEVICE ON CALL — Medical device titan Medtronic (NYSE:MDT) announced late last week that the FDA had put its highest-risk label on a company recall of certain guidewires. The agency deemed the recall […]

• Friday, November 15th, 2013

Analyst say that diagnostics maker Volcano is looking more and more like an attractive target for the likes of Medtronic or Abbott Labs. MASSDEVICE ON CALL — Diagnostics and stents maker Volcano (NSDQ:VOLC) may be primed for acquisition, with a raft of analysts’ groups debating only the timing of a buy. Volcano’s stents and stent placement and evaluation […]

• Monday, November 11th, 2013

The Supreme Court heard oral arguments in Medtronic (MDT) vs. Boston Scientific (BSX) in a patent litigation lawsuit Tuesday. Chances are the Minnesota-based medical device company will win this one. Luckily for Boston Scientific, logic doesn’t always play into legal interpretation. In 1991, Boston Scientific made a licensing agreement with Medtronic for its CRT medical device technology and its […]

• Monday, November 11th, 2013

MINNEAPOLIS – Nov. 7, 2013 – Medtronic, Inc. (NYSE:MDT) today announced FDA approval of its Lead Integrity Alert (LIA) software for use with non-Medtronic leads. Proprietary and exclusive software that resides in Medtronic defibrillators, LIA is now approved to report performance issues on Durata and Riata defibrillator leads (St. Jude Medical) and Endotak (Boston Scientific) […]

• Thursday, October 31st, 2013

Medtronic Inc’s CoreValve heart valve implant significantly lowered death and stroke rates in frail, elderly patients with severe aortic stenosis who were considered too ill for surgery, according to data from a late-stage clinical trial. Medtronic is preparing to launch the product in the United States, pending regulatory approval. It will compete with Edwards Lifesciences’ […]